IL149087A0 - A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium - Google Patents

A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium

Info

Publication number
IL149087A0
IL149087A0 IL14908700A IL14908700A IL149087A0 IL 149087 A0 IL149087 A0 IL 149087A0 IL 14908700 A IL14908700 A IL 14908700A IL 14908700 A IL14908700 A IL 14908700A IL 149087 A0 IL149087 A0 IL 149087A0
Authority
IL
Israel
Prior art keywords
factory scale
producing crystalline
scale process
crystalline atorvastatin
hemi calcium
Prior art date
Application number
IL14908700A
Other languages
English (en)
Original Assignee
Warner Lambert Res & Dev Ie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11042528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL149087(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Res & Dev Ie filed Critical Warner Lambert Res & Dev Ie
Publication of IL149087A0 publication Critical patent/IL149087A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL14908700A 1999-12-17 2000-12-18 A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium IL149087A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE9900132 1999-12-17
PCT/IE2000/000150 WO2001044180A1 (fr) 1999-12-17 2000-12-18 Procede de production a l'echelle industrielle de sel d'hemi-calcium trihydrate d'atorvastatine cristallise

Publications (1)

Publication Number Publication Date
IL149087A0 true IL149087A0 (en) 2002-11-10

Family

ID=11042528

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14908700A IL149087A0 (en) 1999-12-17 2000-12-18 A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium
IL149087A IL149087A (en) 1999-12-17 2002-04-11 Process on a plant-based scale for the creation of the atroustate triad wire

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL149087A IL149087A (en) 1999-12-17 2002-04-11 Process on a plant-based scale for the creation of the atroustate triad wire

Country Status (13)

Country Link
US (1) US6600051B2 (fr)
EP (2) EP1237865B1 (fr)
JP (1) JP2003517038A (fr)
AT (1) ATE309985T1 (fr)
AU (1) AU776613B2 (fr)
CA (1) CA2388226A1 (fr)
DE (1) DE60024133T2 (fr)
ES (1) ES2252088T3 (fr)
HU (1) HUP0203708A3 (fr)
IL (2) IL149087A0 (fr)
MX (1) MXPA02004078A (fr)
WO (1) WO2001044180A1 (fr)
ZA (1) ZA200203648B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69616808T2 (de) 1995-07-17 2002-05-29 Warner Lambert Co Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrol-1-heptancarbonsäure hemi calcium salz (atorvastatin)
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
PL367943A1 (en) * 2001-06-29 2005-03-07 Warner-Lambert Company Llc Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
US7074818B2 (en) * 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
DE03713610T1 (de) * 2002-02-15 2005-10-20 Teva Pharma Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium
KR20090045420A (ko) 2002-02-19 2009-05-07 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미-칼슘 용매화합물의 탈용매화
WO2004050618A2 (fr) * 2002-11-28 2004-06-17 Teva Pharmaceutical Industries Ltd. Forme cristalline
EP1424324A1 (fr) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Forme cristalline F de calcium d'atorvastatine
JP2007536373A (ja) 2004-05-05 2007-12-13 ファイザー・プロダクツ・インク アトルバスタチンの塩形態
WO2006008091A2 (fr) * 2004-07-16 2006-01-26 Lek Pharmaceuticals D.D. Produits de degradation oxydante du calcium d'atorvastatine
BRPI0610344A2 (pt) * 2005-12-13 2016-11-29 Teva Pharma forma cristalizada do atorvastatin hemi-calcium, processo para sua preparação, produto famacêutico derivado e seu uso medicinal
WO2008157681A1 (fr) * 2007-06-20 2008-12-24 Coating Excellence International Llc Sac à fond plat
GR1006173B (el) * 2007-12-21 2008-11-26 Ανωνυμος Φαρμακευτικη-Χημικη Βιομηχανια Medichromα.Ε. Χημικη συνθεση του (3r, 5r) - διυδροξυ - 7 - [2-(4-φθοροφαινυλ) - 5 - σοπροπυλ - 3 - φαινυλ - 4 - φαινυλκαρβαμοϋλο - πυρρολυλο - τριενυδρο - επτανοϊκου ασβεστιου, εφαρμογη φαρμακευτικου σκευασματος και παραγωγικη διαδικασια
CN103483238B (zh) * 2013-08-20 2014-12-31 蚌埠丰原医药科技发展有限公司 阿托伐他汀钙三水合物的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
DE69616808T2 (de) * 1995-07-17 2002-05-29 Warner Lambert Co Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrol-1-heptancarbonsäure hemi calcium salz (atorvastatin)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
HU226465B1 (en) 1996-07-29 2008-12-29 Warner Lambert Co Improved process for the synthesis of protected esters of (s)-3,4-dihydroxybutyric acid
IL135562A (en) 1997-12-19 2005-08-31 Warner Lambert Exp Ltd Process for the synthesis of cis-1,3-diols and a synergistic combination of trialkylborane and dialkylalkoxyborane for such synthesis

Also Published As

Publication number Publication date
IL149087A (en) 2006-12-31
ES2252088T3 (es) 2006-05-16
DE60024133T2 (de) 2006-08-03
JP2003517038A (ja) 2003-05-20
MXPA02004078A (es) 2002-10-11
EP1237865A1 (fr) 2002-09-11
AU2544001A (en) 2001-06-25
EP1237865B1 (fr) 2005-11-16
HUP0203708A3 (en) 2003-11-28
US20020156294A1 (en) 2002-10-24
CA2388226A1 (fr) 2001-06-21
ZA200203648B (en) 2003-02-10
DE60024133D1 (de) 2005-12-22
EP1584616A1 (fr) 2005-10-12
WO2001044180A1 (fr) 2001-06-21
ATE309985T1 (de) 2005-12-15
US6600051B2 (en) 2003-07-29
HUP0203708A2 (hu) 2003-03-28
AU776613B2 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
IL149087A0 (en) A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium
EP0196174A3 (en) Means for sequential solid phase organic synthesis and methods using the same
AU8691691A (en) Mineral wool products for the cultivation of plants
HUP9903634D0 (en) Process for producing amorphous atorvastatin calcium salt
AU582959B2 (en) Process for preparing a water repellent calcium silicate shaped product
GB0002952D0 (en) Process for producing kahalalide F compounds
MY145265A (en) Amorphous ritonavir
EP0807432A3 (fr) Procédé pour la fabrication d'une préparation médicale contenant du sulfate de calcium et une préparation médicale contenant du sulfate de calcium
HUP0203798A3 (en) A process for producing crystalline atorvastatin calcium
IL133249A0 (en) Ortho-metalation process for the synthesis of 2-substituted-1-(tetrazol-5-yl) benzenes
EP0312988A3 (fr) Agent gélifiant du type argile organophile et procédés de préparation d'agents gélifiants du type argile organophile
CA2287464A1 (fr) Procede de production de borate de calcium
EP0857158A4 (fr) Procede d'elaboration de borate de calcium
CA2177145A1 (fr) Procede pour produire un amidon cationique
CA2143357A1 (fr) Materiau pouvant servir d'agent de stabilisation des sols et de sol de substitution
AU7475600A (en) Process for supplying a gaseous mixture to an autothermal reactor
HU9200387D0 (en) Process for the production of homoserin lactons
SE9000897L (sv) Vaextodlingsmedium av torv
AU4809099A (en) Feeding device and process and feeding system which utilise the feeding device
LV12565A (en) Means for obtaining mineral salts and/or fertilizers their transportiation and storage
MY136783A (en) Process for producing calcium carbonate
VN157U (en) Mixture for producing phosphatic fertilizer by pyrogenic processes
TW197444B (en) Method of synthesizing N-phosphorous methyl carboxyglycine
MX9602046A (es) Proceso para la produccion de borato de calcio sintetico.
JPS6410482B2 (fr)

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed